Effectiveness of Convalescent Plasma for Treatment of COVID-19 Patients

Shanshan Chen, Chunya Lu, Ping Li, Satoshi Tanikawa, Huaqi Wang, Qiankun Yang, Liyinghui Chen, Jianbin Li, Hongwei Ma, Qian Sang, Jing Li, Luyang Xu, Xiangjin Song, Fangfang Li, Yi Zhang, Yi Kang, Lihua Xing, Guojun ZhangmedRxiv 2020 · DOI

Abstract

During the initial outbreak of COVID-19, the search for effective treatments was a global priority. This study evaluates the effectiveness and safety of convalescent plasma (CP) therapy in 16 patients with severe and critically ill COVID-19. Following transfusion, 80% of patients who were initially positive for viral nucleic acid turned negative within 2 to 8 days. Severe patients demonstrated a significantly faster viral clearance compared to critically ill patients. Additionally, C-reactive protein (CRP) levels declined significantly within 24 hours of treatment. No adverse events were observed, suggesting that CP is a safe and potentially effective intervention, particularly when administered before the onset of critical illness.

Introduction

In the early months of the COVID-19 pandemic, clinicians faced a dire lack of specific antiviral drugs or vaccines. Mortality rates for critically ill patients were alarmingly high, often exceeding 50% in early reports from Wuhan. This research explores the use of convalescent plasma—blood plasma from recovered patients containing specific antibodies—as a form of "passive immunotherapy." Historically used for diseases like the Spanish Flu and SARS, CP was hypothesized to neutralize the SARS-CoV-2 virus and dampen the systemic inflammatory response that often leads to multi-organ failure.

Methods

The researchers conducted a case series study involving 16 patients (5 severe, 11 critically ill) at two hospitals in Henan Province, China. The patient cohort had an average age of 65, with 62.5% suffering from comorbidities such as hypertension or diabetes.

Treatment and Monitoring

Patients received 200–400 mL of ABO-compatible convalescent plasma. Plasma was collected from 30 recovered donors who had been symptom-free for at least two weeks. Crucially, the researchers measured specific anti-SARS-CoV-2 antibody levels in the donor plasma using magnetic particle chemiluminescence to ensure the presence of neutralizing agents.

The primary outcome measured was the time taken for the viral nucleic acid amplification (NAA) test to turn negative. Secondary outcomes included laboratory markers such as C-reactive protein (CRP), white blood cell counts, and liver/heart enzymes, measured at baseline (d0), day 1 (d1), and day 3 (d3) post-transfusion.

Key Results

Viral Clearance

At the start of the study, 10 of the 16 patients were consistently positive for viral NAA. Following CP transfusion, 8 of these 10 patients (80%) became negative between day 2 and day 8.

Reduction in Inflammation

Beyond viral neutralization, CP appeared to have a rapid anti-inflammatory effect. CRP levels, a key indicator of systemic inflammation and the "cytokine storm," showed a statistically significant decline just one day after transfusion ($P = 0.017$), dropping to approximately 63% of baseline levels.

Safety

No adverse events or allergic reactions were observed during or after the plasma transfusions, supporting the safety profile of CP in this patient population.

Discussion: The Importance of Timing and Titer

The study revealed two critical factors influencing the success of convalescent plasma therapy:

  1. The Window of Opportunity: Severe patients cleared the virus significantly faster than those in the critically ill group (mean rank 2.17 vs 5.90, $P = 0.036$). This suggests that CP is most effective when administered before the disease progresses to a stage requiring mechanical ventilation or extracorporeal membrane oxygenation (ECMO).
  2. Antibody Concentration: Two critically ill patients failed to clear the virus and eventually succumbed to the disease. Both had received plasma from the same donor, which was later found to have a very low antibody concentration (16.79 AU/mL). This finding underscores the necessity of screening donor plasma for high antibody titers rather than simply confirming the presence of antibodies.

Conclusion and Limitations

While the results are promising, the authors acknowledge several limitations. The small sample size (n=16) and the lack of a randomized control group mean that definitive claims regarding mortality cannot be made. Furthermore, many patients received the intervention late in their disease course (averaging 23 days after symptom onset), which may have limited the treatment's potential benefits.

Despite these limitations, the study provides early evidence that convalescent plasma can safely shorten viral shedding and reduce inflammation in COVID-19 patients. Future large-scale randomized controlled trials (RCTs) are necessary to validate these findings and standardize the antibody levels required for effective treatment.

Trial Registration: Chinese Clinical Trial Registry; No.: ChiCTR2000030627

Summary updated

Abstract

Abstract Background and objective The outbreak of COVID-19 has become a global health concern. In this study, we evaluate the effectiveness and safety of convalescent plasma therapy in patients with severe and critically ill COVID-19. Methods Sixteen COVID-19 patients received transfusion of anti-COVID-19 antibody-positive convalescent plasma. The main outcome was time for viral nucleic acid amplification (NAA) test turning negative. Clinical laboratory parameters were measured at the baseline (d0) before plasma transfusion, and day 1 (d1), day 3 (d3) after transfusion as well. Results Among the 16 patients, 10 of them had a consistently positive result of viral NAA test before convalescent plasma transfusion. Eight patients (8/10) became negative from day 2 to day 8 after transfusion. Severe patients showed a shorter time for NAA test turning negative after transfusion (mean rank 2.17 vs 5·90, P = 0.036). Two critically ill patients transfused plasma with lower antibody level remained a positive result of NAA test. CRP level demonstrated a decline 1 day after convalescent plasma treatment, compared with the baseline ( P = 0.017). No adverse events were observed during convalescent plasma transfusion. Conclusions Viral NAA test of most patients with COVID-19 who received convalescent plasma transfusion turned negative on the 2nd to 8th days after transfusion, and the negative time of severe patients was shorter than that of critically ill patients. Trial Registration Chinese Clinical Trial Registry; No.: ChiCTR2000030627 URL: http://www.chictr.org
BibTeX
@misc{chen2020effectiveness,
  author = {Shanshan Chen and Chunya Lu and Ping Li and Satoshi Tanikawa and Huaqi Wang and Qiankun Yang and Liyinghui Chen and Jianbin Li and Hongwei Ma and Qian Sang and Jing Li and Luyang Xu and Xiangjin Song and Fangfang Li and Yi Zhang and Yi Kang and Lihua Xing and Guojun Zhang},
  title = {{Effectiveness of Convalescent Plasma for Treatment of COVID-19 Patients}},
  year = {2020},
  doi = {10.1101/2020.08.02.20166710},
  howpublished = {medRxiv},
}
Figure